Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Director | June 09, 2026 | June 11, 2026 |
| INTERNATIONAL FLAVORS & FRAGRANCES INCIFF · Entity 3234 | Director | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,263 |
Reported balance
After 2026-06-09 transaction · row 1
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 1,505 · Balance 11,263 F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026.
INTERNATIONAL FLAVORS & FRAGRANCES INC
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Disposition to issuer · Disposed 2,281 · Balance 0 F1: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F2: Represent RSUs granted under the Non-Employee Director Compensation Program. F4: Upon the vesting of RSUs on May 1, 2026, the reporting person deferred the receipt of 2,281 shares of Common Stock and received instead 2,281 Stock Equivalent Units ("Units") pursuant to the Company's deferredcompensation plan. F3: On September 2, 2025, the reporting person was granted 2,281 RSUs, all of which vested on May 1, 2026. |
| Stock Equivalent UnitSEC Table II · derivative / convertible security | Direct | 2,281 |
Reported balance
After 2026-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-01 · Grant · Acquired 2,281 · Balance 2,281 F5: The Units convert to Common Stock on a one-for-one basis. F4: Upon the vesting of RSUs on May 1, 2026, the reporting person deferred the receipt of 2,281 shares of Common Stock and received instead 2,281 Stock Equivalent Units ("Units") pursuant to the Company's deferredcompensation plan. F6: The Units are payable in Common Stock upon the earlier of the reporting person ceasing to serve as a member of the Company's Board of Directors or January 1 following retirement. |
Filing footnotes · ownership attribution and instrument terms
F1: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis.
F2: Represent RSUs granted under the Non-Employee Director Compensation Program.
F3: On September 2, 2025, the reporting person was granted 2,281 RSUs, all of which vested on May 1, 2026.
F4: Upon the vesting of RSUs on May 1, 2026, the reporting person deferred the receipt of 2,281 shares of Common Stock and received instead 2,281 Stock Equivalent Units ("Units") pursuant to the Company's deferredcompensation plan.
F5: The Units convert to Common Stock on a one-for-one basis.
F6: The Units are payable in Common Stock upon the earlier of the reporting person ceasing to serve as a member of the Company's Board of Directors or January 1 following retirement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 21:44 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,505 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000062 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,263 F1 · shares: The restricted stock units vest on the earlier of (i) the next annual meeting or (ii) the anniversary of the date of grant of June 9, 2026. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:17 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantStock Equivalent Unit · Derivative | 2,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-004943 · doc4.xml · derivative · entry 2 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,281 Underlying: Common Stock · 2,281 shares Expires not disclosed F5 · derivative.exercise_price: The Units convert to Common Stock on a one-for-one basis. F4 · price: Upon the vesting of RSUs on May 1, 2026, the reporting person deferred the receipt of 2,281 shares of Common Stock and received instead 2,281 Stock Equivalent Units ("Units") pursuant to the Company's deferredcompensation plan. F6 · derivative.exercise_date: The Units are payable in Common Stock upon the earlier of the reporting person ceasing to serve as a member of the Company's Board of Directors or January 1 following retirement. F6 · derivative.expiration_date: The Units are payable in Common Stock upon the earlier of the reporting person ceasing to serve as a member of the Company's Board of Directors or January 1 following retirement. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:17 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | Disposition to issuerRestricted Stock Units · Derivative | 2,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-004943 · doc4.xml · derivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,281 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F2 · shares: Represent RSUs granted under the Non-Employee Director Compensation Program. F4 · price: Upon the vesting of RSUs on May 1, 2026, the reporting person deferred the receipt of 2,281 shares of Common Stock and received instead 2,281 Stock Equivalent Units ("Units") pursuant to the Company's deferredcompensation plan. F3 · derivative.exercise_date: On September 2, 2025, the reporting person was granted 2,281 RSUs, all of which vested on May 1, 2026. F3 · derivative.expiration_date: On September 2, 2025, the reporting person was granted 2,281 RSUs, all of which vested on May 1, 2026. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 20:29 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 2,903 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-004737 · doc4.xml · derivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,903 Underlying: Common Stock · 2,903 shares Expires 2027-04-29 F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F2 · shares: Represent RSUs granted under the Non-Employee Director Compensation Program. F3 · derivative.exercise_date: The RSUs will vest on the one-year anniversary of the grant date. F3 · derivative.expiration_date: The RSUs will vest on the one-year anniversary of the grant date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 00:09 UTC | INTERNATIONAL FLAVORS & FRAGRANCES INC IFF · Entity 3234 | GrantRestricted Stock Units · Derivative | 2,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-25-007748 · doc4.xml · derivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,281 Underlying: Common Stock · 2,281 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Units ("RSUs") convert to Common Stock on a one-for-one basis. F2 · derivative.expiration_date: The RSUs will vest on May 1, 2026. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:47 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 2,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017763 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,758 Read SEC document |
| June 21, 2024 Filed Jun 25, 2024 21:19 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-019239 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,388 Read SEC document |
| June 26, 2023 Filed Jun 28, 2023 23:05 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 960 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019546 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,048 Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:02 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-017796 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,088 Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:26 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-021331 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,718 Read SEC document |
| February 09, 2021 Filed Feb 10, 2021 21:31 UTC | BIOGEN INC. BIIB · Entity 1675 | PurchaseCommon Stock | 898 | $267.00 | $239,766.00 |
DisclosureSEC source: 0001127602-21-004941 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,943 Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 890 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-019025 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,045 Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,155 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-022435 · form4.xml · nonDerivative · entry 1 Mantas Jesus B · CIK 0001777331 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.